[go: up one dir, main page]

ATE273009T1 - Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel - Google Patents

Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel

Info

Publication number
ATE273009T1
ATE273009T1 AT96938819T AT96938819T ATE273009T1 AT E273009 T1 ATE273009 T1 AT E273009T1 AT 96938819 T AT96938819 T AT 96938819T AT 96938819 T AT96938819 T AT 96938819T AT E273009 T1 ATE273009 T1 AT E273009T1
Authority
AT
Austria
Prior art keywords
prostaglandins
analogues
lowering agents
substituted tetrahydrofuran
eye
Prior art date
Application number
AT96938819T
Other languages
English (en)
Inventor
Robert D Selliah
Mark R Hellberg
Peter G Klimko
Verney L Sallee
Paul W Zinke
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of ATE273009T1 publication Critical patent/ATE273009T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96938819T 1995-12-22 1996-11-12 Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel ATE273009T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US986695P 1995-12-22 1995-12-22
PCT/US1996/017900 WO1997023223A1 (en) 1995-12-22 1996-11-12 Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives

Publications (1)

Publication Number Publication Date
ATE273009T1 true ATE273009T1 (de) 2004-08-15

Family

ID=21740176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96938819T ATE273009T1 (de) 1995-12-22 1996-11-12 Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel

Country Status (11)

Country Link
US (4) US5994397A (de)
EP (1) EP0869794B1 (de)
JP (1) JP3032302B2 (de)
AT (1) ATE273009T1 (de)
AU (1) AU714272B2 (de)
CA (1) CA2236582C (de)
DE (1) DE69633136T2 (de)
ES (1) ES2225897T3 (de)
HK (1) HK1010874A1 (de)
MX (1) MX9805020A (de)
WO (1) WO1997023223A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019680A1 (en) * 1996-11-01 1998-05-14 Alcon Laboratories, Inc. Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
AU1709699A (en) 1997-12-22 1999-07-12 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
IL145122A0 (en) 1999-03-05 2002-06-30 Procter & Gamble C16 unsaturated fp-selective prostaglandin analogs
US6214611B1 (en) 1999-04-12 2001-04-10 Chirotech Technology Limited Process for the preparation of prostaglandin precursors
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
GB0012249D0 (en) * 2000-05-19 2000-07-12 Chirotech Technology Ltd Process for the preparation of 11-oxaprostaglandins
US6441196B2 (en) 2000-05-19 2002-08-27 Alcon, Inc. Processes and novel intermediates for 11-oxa prostaglandin synthesis
US20020133009A1 (en) * 2001-03-13 2002-09-19 Lambrou George N. Method for opening potassium channels
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
AU2009340420A1 (en) 2008-10-29 2010-08-26 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
ES2553827T3 (es) 2009-05-01 2015-12-14 Aerie Pharmaceuticals, Inc. Inhibidores de mecanismo doble para el tratamiento de enfermedad
ES2695931T3 (es) 2009-11-09 2019-01-11 Allergan Inc Composiciones y métodos para estimular el crecimiento del pelo
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
WO2014144781A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
AU2018243687C1 (en) 2017-03-31 2020-12-24 Alcon Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
EP3849555A4 (de) 2018-09-14 2022-05-04 Aerie Pharmaceuticals, Inc. Aryl-cyclopropyl-amino-isochinolinyl-amidverbindungen
US20240043438A1 (en) * 2020-08-11 2024-02-08 Arun K. Ghosh Methods for making darunavir p2-ligand precursors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883659A (en) * 1973-05-18 1975-05-13 Ciba Geigy Corp 9-Oxaprostaglandin compositions
US4088779A (en) * 1973-05-18 1978-05-09 Ciba-Geigy Corporation 9-Oxaprostaglandins
DE2436332A1 (de) * 1974-07-27 1976-02-12 Knoll Ag Substituierte tetrahydrofurane und verfahren zu deren herstellung
DE2460977A1 (de) * 1974-12-21 1976-07-01 Knoll Ag Sterisch einheitliche 11-oxaprostaglandine und verfahren zu deren herstellung
US4133948A (en) 1975-01-16 1979-01-09 Chembro Holdings (Proprietary) Limited Monosaccharides and products resulting therefrom
GB1532551A (en) * 1975-01-16 1978-11-15 Chembro Holdings Pty Ltd Furo(3,4-6)furone derivatives and their preparation
ZA752806B (en) * 1975-04-30 1976-12-29 Chembro Holdings Pty Ltd Novel 11-oxa-prostaglandin analogues derivatives thereof and methods for their preparation
DE2739277C2 (de) * 1976-09-15 1982-06-09 Pfizer Inc., 10017 New York, N.Y. Prostaglandinderivate, Verfahren zu deren Herstellung und deren Verwendung
US5574066A (en) * 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
KR950032113A (ko) * 1994-03-22 1995-12-20 우에노 도시오 프로스타글란딘 에프 에스테르
SE9401087D0 (sv) * 1994-03-31 1994-03-31 Pharmacia Ab New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Also Published As

Publication number Publication date
DE69633136T2 (de) 2005-09-01
CA2236582A1 (en) 1997-07-03
AU714272B2 (en) 1999-12-23
EP0869794A1 (de) 1998-10-14
CA2236582C (en) 2004-08-17
HK1010874A1 (en) 1999-07-02
US6197812B1 (en) 2001-03-06
US6369102B2 (en) 2002-04-09
MX9805020A (es) 1998-09-30
US6025392A (en) 2000-02-15
US20010029265A1 (en) 2001-10-11
US5994397A (en) 1999-11-30
EP0869794B1 (de) 2004-08-11
WO1997023223A1 (en) 1997-07-03
ES2225897T3 (es) 2005-03-16
JPH11502234A (ja) 1999-02-23
AU7610696A (en) 1997-07-17
DE69633136D1 (de) 2004-09-16
JP3032302B2 (ja) 2000-04-17

Similar Documents

Publication Publication Date Title
ATE273009T1 (de) Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE202557T1 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
DK0674684T3 (da) Polymerisérbare gule farvestoffer og deres anvendelse i oftalmiske linser
ATE480240T1 (de) Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom
DE69630325D1 (de) Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern
DK1920764T4 (da) Fluprostenolisopropylester til anvendelse ved behandling af glaukom og okulær hypertension
BR0013255A (pt) Agente substitutivo lacrimal
PT865294E (pt) Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob
WO1998021182A3 (en) Use of cis-δ4 analogs of prostaglandins as ocular hypotensives
ATE232400T1 (de) Verwendung von einem farbstoff zum erleichtern der augennetzhautoperationen
DE69116705D1 (de) Antiglancoma-Zusammensetzungen enthaltend 3-Arylcarbonyl-1-aminoalkyl-1H-indol
FR2754712B1 (fr) Compositions ophtalmiques
DE69430521D1 (de) Anwendung von Prostagrandin-Analogen für die Behandlung von Glaukome und okuläre Hypertension
BG102064A (en) Method for increasing the retinal blood circulation
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
MX9201785A (es) Composiciones oftalmicas que comprenden combinaciones de un inhibidor de anhidrasa carbonico y antagonistas beta-adrenergicos.
ES2079872T3 (es) Derivados hipotensores oculares de la 2-descarboxil-2-aciltioalquilprostaglandina.
ATE289198T1 (de) Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
PT1169026E (pt) Utilizacao de activadores de ap-1 no tratamento do glaucoma e da hipertensao ocular
ATE138574T1 (de) Verwendung von prostaglandin f3alpha als okulares hypotensivum
RU94041113A (ru) Способ лечения кератоконуса
BR9901566A (pt) Análogos cis-delta4 de prostaglandinas como hipotensores oculares
RU95111135A (ru) Способ лечения нисходящих атрофий зрительного нерва методом прямого электрофореза

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties